Company: TELO
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001641172-25-010298
Chunk: 76

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-05-14
Form: 10-Q
Item: Item 1
Chunk 76
---
 as we advance the preclinical
activities and studies and initiate clinical trials. In addition, if we obtain regulatory approval for any programs, we expect to incur
significant expenses related to production of sales, marketing, and distribution to the extent that such sales, marketing and distribution
are not the responsibility of potential collaborators. We expect to incur additional costs associated with operating as a public company.

We
had net losses of $2.2 million and $6.3 million for the three months ended March 31, 2025 and 2024, respectively.

Highlights-Three
Months Ended March 31, 2025

●
On January 7, 2025, we announced a preclinical progeria lifespan study conducted in collaboration with Nagi Bioscience SA. Utilizing
C. elegans (nematode) models, in which the study demonstrated restoration of shortened lifespan and normalization of accelerated aging
with Telomir-1.

●
On January 28, 2025, we announced that our studies demonstrated the ability of Telomir-1 to fully reverse copper-induced elevation of
ROS and provide robust cellular protection against copper toxicity.

●
On February 18, 2025, we announced that our studies had demonstrated the ability of Telomir-1 to significantly reverse copper and iron-induced
elevation of Reactive Oxygen Species (ROS).

●
On February 21, 2025, we announced that Telomir-1 had successfully captured and stabilized both Silver(I) (Ag⁺) and the highly
reactive Silver(II) (Ag²⁺) in a biologically compatible form.

●
On February 26, 2025, we announced that Telomir-1 fully reverses calcium dysregulation-an often-overlooked yet fundamental driver of
cell death, aging, and disease progression-in multiple human cell lines.

●
On March 19, 2025, we announced that Telomir-1 reduces tumor size by approximately 50% in a prostate cancer animal model using highly
aggressive human prostate cancer cells.

●
On May 7, 2025, we announced new preclinical data showing that our lead oral drug candidate, Telomir-1, reverses multiple hallmarks of
cellular decline across several human cell lines. The findings include improved mitochondrial activity, reduced oxidative stress, restored
calcium balance, and protection from toxic metal effects-offering a mechanistic foundation for our new research initiatives in